
News|Articles|December 1, 2012
Aubagio (Teriflunomide)
New molecular entity: FDA approved teriflunomide (Aubagio, Genzyme, a Sanofi-Aventis company), a pyrimidine synthesis inhibitor, for the treatment of patients with relapsing forms of multiple sclerosis (MS).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Immune system targets single beta cells before Type 1 diabetes symptoms show
2
2025 FDA added indications to dermatologic medications
3
Novel tracer can identify lung lesions in those with connective tissue diseases
4
Winter exposes how closely eczema, asthma and allergies are linked
5

















































